Thomas Haberl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Haberl has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Zimpfer
Department of Cardiac and Thoracic Aortic Surgery, Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Dominik Wiedemann
Karl Landsteiner University of Health Sciences , Dr. Karl-Dorrek-Straße 30, Krems 3500
3 shared publications - Günther Laufer
Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, Austria
3 shared publications - Julia Riebandt
Department of Cardiac Surgery, Medical University of Vienna, 1090 Vienna, Austria
3 shared publications Alexandra Kaider
Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria
2 shared publications- Heinrich Schima
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
2 shared publications
Latest Publications
- Open Access
Awake Implementation of Extracorporeal Life Support in Refractory Cardiogenic Shock
Background and objectives: Extracorporeal life support (ECLS) is a widely accepted and effective strategy for use in patients presenting with refractory cardiogenic shock. Implantation in awake and non-intubated patients allows for optimized evaluation of further therapy options while avoiding potential side effects associated with the need for sedation and intubation. The aim of the study was the assessment of safety and feasibility of awake ECLS implementation and of outcomes in patients treated with this concept. Materials and Methods: We retrospectively reviewed the concept of awake ECLS implantation in 16 consecutive patients (mean age 58 ± 8 years; male: 88%; ischemic cardiomyopathy: 50%) from 02/2017 to 01/2021. Study endpoints were survival to weaning or bridging to durable support or organ replacement and development of end-organ function and hemodynamic parameters on ECLS. Results: Fourteen patients (88%) were able to be successfully transitioned to definite therapy options. ECLS support stabilized end-organ function, led to a decrease in mean lactate levels (5.3 ± 3.7 mmol/L at baseline to 1.9 ± 1.3 mmol/L 12 h after ECLS start; p = 0.01) and improved hemodynamics (median central venous pressure 20 ± 5 mmHg vs. 10 ± 2 mmHg, p = 0.001) over a median duration of two days (1–8 days IQR). Two patients (13%) died on ECLS support due to multi-organ dysfunction syndrome. Survival to discharge of initially successfully bridged or weaned patients was 64%. Conclusions: Awake ECLS implantation is feasible and safe with the key advantage of omitting or delaying general anesthesia and intubation, with their associated risks in cardiogenic-shock patients, facilitating further decision making.
Open AccessAwake Implementation of Extracorporeal Life Support in Refractory Cardiogenic Shock
Background and objectives: Extracorporeal life support (ECLS) is a widely accepted and effective strategy for use in patients presenting with refractory cardiogenic shock. Implantation in awake and non-intubated patients allows for optimized evaluation of further therapy options while avoiding potential side effects associated with the need for sedation and intubation. The aim of the study was the assessment of safety and feasibility of awake ECLS implementation and of outcomes in patients treated with this concept. Materials and Methods: We retrospectively reviewed the concept of awake ECLS implantation in 16 consecutive patients (mean age 58 ± 8 years; male: 88%; ischemic cardiomyopathy: 50%) from 02/2017 to 01/2021. Study endpoints were survival to weaning or bridging to durable support or organ replacement and development of end-organ function and hemodynamic parameters on ECLS. Results: Fourteen patients (88%) were able to be successfully transitioned to definite therapy options. ECLS support stabilized end-organ function, led to a decrease in mean lactate levels (5.3 ± 3.7 mmol/L at baseline to 1.9 ± 1.3 mmol/L 12 h after ECLS start; p = 0.01) and improved hemodynamics (median central venous pressure 20 ± 5 mmHg vs. 10 ± 2 mmHg, p = 0.001) over a median duration of two days (1–8 days IQR). Two patients (13%) died on ECLS support due to multi-organ dysfunction syndrome. Survival to discharge of initially successfully bridged or weaned patients was 64%. Conclusions: Awake ECLS implantation is feasible and safe with the key advantage of omitting or delaying general anesthesia and intubation, with their associated risks in cardiogenic-shock patients, facilitating further decision making.
- Open Access
- 1 September 2021
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 162 (3) , 803-811
Conduction disturbances following surgical aortic valve replacement with a rapid-deployment bioprosthesis
- 1 September 2021
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 162 (3) , 803-811
Open AccessConduction disturbances following surgical aortic valve replacement with a rapid-deployment bioprosthesis
- Open Access
- 22 May 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (9) , 1078-1088
Molecular‐level HLA mismatch is associated with rejection and worsened graft survival in heart transplant recipients – a retrospective study
Background The aim was to evaluate the association of molecular‐level human leukocyte antigen (HLA) mismatching with post‐transplant graft survival, rejection and cardiac allograft vasculopathy (CAV). Methods We retrospectively analysed all primary cardiac transplant recipients between 01/1984‐06/2016. 1,167 patients fulfilled inclusion criteria and had HLA typing information available. In 312 donor‐recipient pairs, typing at serological split antigen level was available. We used the Epitope MisMatch Algorithm to calculate the number of amino acid differences in antibody‐verified HLA eplets (amino acid mismatch‐load (AAMM)) between donor and recipient. Results Patients with a higher HLA‐DR AAMM load had inferior 1‐year graft survival (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.01‐1.28). The HLA‐AB AAMM load showed no impact on graft survival. In the subgroup with available split‐level information, we observed an inferior graft survival for a higher HLA‐DR AAMM load 3 months after transplantation (HR, 1.22; 95% CI, 1.04‐1.44) and a higher risk for rejection for an increasing HLA‐AB (HR, 1.70; 95% CI, 1.29‐2.24) and HLA‐DR (HR, 1.32; 95% CI, 1.09‐1.61) AAMM load. No impact on the development of CAV was found. Conclusions Molecular‐level HLA mismatch analysis could serve as a tool for risk stratification after heart transplantation and might take us one step further into precision medicine.
- 22 May 2020
- Published by Frontiers Media SA in Transplant International
- Vol. 33 (9) , 1078-1088
Open AccessMolecular‐level HLA mismatch is associated with rejection and worsened graft survival in heart transplant recipients – a retrospective study
Background The aim was to evaluate the association of molecular‐level human leukocyte antigen (HLA) mismatching with post‐transplant graft survival, rejection and cardiac allograft vasculopathy (CAV). Methods We retrospectively analysed all primary cardiac transplant recipients between 01/1984‐06/2016. 1,167 patients fulfilled inclusion criteria and had HLA typing information available. In 312 donor‐recipient pairs, typing at serological split antigen level was available. We used the Epitope MisMatch Algorithm to calculate the number of amino acid differences in antibody‐verified HLA eplets (amino acid mismatch‐load (AAMM)) between donor and recipient. Results Patients with a higher HLA‐DR AAMM load had inferior 1‐year graft survival (hazard ratio [HR], 1.14; 95% confidence interval [CI], 1.01‐1.28). The HLA‐AB AAMM load showed no impact on graft survival. In the subgroup with available split‐level information, we observed an inferior graft survival for a higher HLA‐DR AAMM load 3 months after transplantation (HR, 1.22; 95% CI, 1.04‐1.44) and a higher risk for rejection for an increasing HLA‐AB (HR, 1.70; 95% CI, 1.29‐2.24) and HLA‐DR (HR, 1.32; 95% CI, 1.09‐1.61) AAMM load. No impact on the development of CAV was found. Conclusions Molecular‐level HLA mismatch analysis could serve as a tool for risk stratification after heart transplantation and might take us one step further into precision medicine.
- Open Access
- 24 February 2018
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (S2) , 177-182
Minimally invasive approaches for implantation of left ventricular assist devices
The era of intracorporal continuous flow pumps has initiated significant success of left ventricular assist device (LVAD) surgery. However, median sternotomy has been the only surgical approach for implantation over many years. During the last decade, less-invasive access ways gained popularity. Within this review, we describe our own clinical experience in minimally invasive ventricular assist device (VAD) surgery and summarize the current scientific literature on this topic.
- 24 February 2018
- Published by Springer Nature in Indian Journal of Thoracic and Cardiovascular Surgery
- Vol. 34 (S2) , 177-182
Open AccessMinimally invasive approaches for implantation of left ventricular assist devices
The era of intracorporal continuous flow pumps has initiated significant success of left ventricular assist device (LVAD) surgery. However, median sternotomy has been the only surgical approach for implantation over many years. During the last decade, less-invasive access ways gained popularity. Within this review, we describe our own clinical experience in minimally invasive ventricular assist device (VAD) surgery and summarize the current scientific literature on this topic.
- Open Access
- 1 January 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (S 01) , S1-S110
Micro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices
Objectives: Micro-emboli are detectable as high intensity transient signals (HITS) with Doppler ultrasound in different clinical conditions including patients with left ventricular assist devices (LVAD). In LVAD patients HITS represent micro-emboli of mostly gaseous nature. The cause of their formation, however, has not been determined. Methods: From June 2014 to September 2016 LVAD patients were systematically screed for HITS in the LVAD outflow graft by transthoracic echocardiography. The occurrence of HITS was then correlated with pump thrombus formation (PT) and non-thrombotic outflow graft occlusion. Results: HITS were detected in the outflow graft of 20 LVAD patients (Thoratec Heartmate II n = 12, Heartware HVAD n = 8). HITS correlated with PT in 14 patients (Heartmate II n = 7, HVAD n = 7) and non-thrombotic outflow graft stenosis in 6 patients (Heartmate II n = 5, HVAD n = 1). Patients with PT either underwent thrombolysis (n = 7), pump exchange (n = 2), LVAD weaning (n = 1) or no treatment if no hard clinical treatment indication was present (n = 5). In PT patients HITS disappeared after successful thrombolysis or pump exchange. Of note, pump thrombus formation or non-thrombotic outflow graft stenosis could be macroscopically assured at the time of transplant in the remaining patients. Conclusion: HITS detection by transthoracic echocardiography identifies patients with pump thrombus formation and non-thrombotic outflow graft occlusion and might develop as a very sensitive screening tool for pump pathology and hypocoagulation monitoring.
- 1 January 2017
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 65 (S 01) , S1-S110
Open AccessMicro-Embolic Signals Correlate with Pump Thrombus Formation and Non-Thrombotic Outflow Graft Occlusion in Patients with Left Ventricular Assist Devices
Objectives: Micro-emboli are detectable as high intensity transient signals (HITS) with Doppler ultrasound in different clinical conditions including patients with left ventricular assist devices (LVAD). In LVAD patients HITS represent micro-emboli of mostly gaseous nature. The cause of their formation, however, has not been determined. Methods: From June 2014 to September 2016 LVAD patients were systematically screed for HITS in the LVAD outflow graft by transthoracic echocardiography. The occurrence of HITS was then correlated with pump thrombus formation (PT) and non-thrombotic outflow graft occlusion. Results: HITS were detected in the outflow graft of 20 LVAD patients (Thoratec Heartmate II n = 12, Heartware HVAD n = 8). HITS correlated with PT in 14 patients (Heartmate II n = 7, HVAD n = 7) and non-thrombotic outflow graft stenosis in 6 patients (Heartmate II n = 5, HVAD n = 1). Patients with PT either underwent thrombolysis (n = 7), pump exchange (n = 2), LVAD weaning (n = 1) or no treatment if no hard clinical treatment indication was present (n = 5). In PT patients HITS disappeared after successful thrombolysis or pump exchange. Of note, pump thrombus formation or non-thrombotic outflow graft stenosis could be macroscopically assured at the time of transplant in the remaining patients. Conclusion: HITS detection by transthoracic echocardiography identifies patients with pump thrombus formation and non-thrombotic outflow graft occlusion and might develop as a very sensitive screening tool for pump pathology and hypocoagulation monitoring.
- 23 January 2013
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 61 (S 01) , OP53
Minimal invasive LVAD implantation via bilateral thoracotomy
Objective: A median sternotomy is the standard incision for left ventricular assist device (LVAD) implantation. There are some theoretical advantages of avoiding a median sternotomy in LVAD patients including better right ventricular protection, improved pulmonary function and faster recovery. The present study was designed to evaluate a novel, minimally invasive sternotomy sparing technique for LVAD implantation. Methods: From February 2012 to September 2012 10 patients (mean age 55.5 ± 11.1yrs., 90% male, ischemic heart disease 70%, prior cardiac surgery 10%) with terminal heart failure (Intermacs level 1: 30%, level 2 10%, level 3 40%, level 4 – 7 20%) underwent minimally invasive isolated sternotomy sparing LVAD implantation (Heartware® HVAD n = 9, Thoratect® HMII n = 1). Surgical access was established by a left minithoracotomy directly over the apex, the outflow graft was tunneled to the aorta intrapericardially in all but redo cases. The aortic outflow anastomosis was performed via a right minithoracotomy in the 2nd intercostal space. Circulatory support for LVAD implantation was performed using CPB or ECMO. Results: Sternotomy sparing LVAD implantation was feasible in all patients with no need for conversions. Thirty-day and in-hospital mortality was 0%. Median time on respirator was 2.2 ± 3.4 days, overall in-hospital stay was 32.6 ± 8.5 days. One patient (10%) died during follow-up from pump thrombus formation. One patient underwent surgical revision for postoperative bleeding (retroperitoneal haematoma). We observed no permanent neurological deficits and relevant infections. Conclusion: Minimally invasive sternotomy sparing left ventricular assist device implantation is feasible and safe. The very encouraging results obtained in this initial series justify a broad application of this technique.
- 23 January 2013
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 61 (S 01) , OP53
Minimal invasive LVAD implantation via bilateral thoracotomy
Objective: A median sternotomy is the standard incision for left ventricular assist device (LVAD) implantation. There are some theoretical advantages of avoiding a median sternotomy in LVAD patients including better right ventricular protection, improved pulmonary function and faster recovery. The present study was designed to evaluate a novel, minimally invasive sternotomy sparing technique for LVAD implantation. Methods: From February 2012 to September 2012 10 patients (mean age 55.5 ± 11.1yrs., 90% male, ischemic heart disease 70%, prior cardiac surgery 10%) with terminal heart failure (Intermacs level 1: 30%, level 2 10%, level 3 40%, level 4 – 7 20%) underwent minimally invasive isolated sternotomy sparing LVAD implantation (Heartware® HVAD n = 9, Thoratect® HMII n = 1). Surgical access was established by a left minithoracotomy directly over the apex, the outflow graft was tunneled to the aorta intrapericardially in all but redo cases. The aortic outflow anastomosis was performed via a right minithoracotomy in the 2nd intercostal space. Circulatory support for LVAD implantation was performed using CPB or ECMO. Results: Sternotomy sparing LVAD implantation was feasible in all patients with no need for conversions. Thirty-day and in-hospital mortality was 0%. Median time on respirator was 2.2 ± 3.4 days, overall in-hospital stay was 32.6 ± 8.5 days. One patient (10%) died during follow-up from pump thrombus formation. One patient underwent surgical revision for postoperative bleeding (retroperitoneal haematoma). We observed no permanent neurological deficits and relevant infections. Conclusion: Minimally invasive sternotomy sparing left ventricular assist device implantation is feasible and safe. The very encouraging results obtained in this initial series justify a broad application of this technique.